Point72 Asset Management’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$6.79M Buy
48,700
+5,900
+14% +$826K 0.01% 1491
2025
Q4
$5.25M Buy
+42,800
New +$5.2M 0.01% 1813
2025
Q1
Sell
-150,000
Closed -$13.9M 2230
2024
Q4
$13.9M Buy
+150,000
New +$13.5M 0.03% 588
2018
Q4
Sell
-25,000
Closed -$1.93M 1054
2018
Q3
$1.93M Buy
+25,000
New +$1.89M 0.01% 766
2018
Q1
Sell
-1,000,000
Closed -$71.6M 1004
2017
Q4
$71.6M Buy
+1,000,000
New +$75.9M 0.31% 82
2017
Q3
Sell
-28,700
Closed -$2.03M 935
2017
Q2
$2.03M Hold
28,700
0.01% 646
2017
Q1
$1.95M Buy
+28,700
New +$2.02M 0.01% 676

Other funds holding GILD

Point72 Asset Management's GILD Position: Q1 2026 in Review

Point72 Asset Management opened a new position in Gilead Sciences (GILD) in Q1 2026: 8,808 shares worth $1.23M. The stake represents ﹤0.01% of the portfolio and ranks #2621 among its holdings. This is a return to the name: Point72 Asset Management previously reported a position in GILD as recently as Q2 2025.

Point72 Asset Management first reported a position in GILD in Q4 2014 and has held it in 27 quarters since. The position peaked at $232M in Q1 2018. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Point72 Asset Management held 8,808 shares of Gilead Sciences worth $1.23M as of Q1 2026.
  • Gilead Sciences was a new Point72 Asset Management position in Q1 2026.
  • Gilead Sciences made up ﹤0.01% of Point72 Asset Management's portfolio in Q1 2026, its #2621 holding.
  • Point72 Asset Management first reported a position in Gilead Sciences in Q4 2014 and has held it in 27 quarters since.
  • Point72 Asset Management's Gilead Sciences position peaked at $232M in Q1 2018.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.